DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes |
|
|
| Recruiting | 3 | 330 | Europe, US, RoW | Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo | Diamyd Medical AB | Type 1 Diabetes Mellitus | 12/27 | 12/27 | | |